Topical nepafenac 0.1% for treatment of chronic uveitic cystoid macular edema

To describe the efficacy of nepafenac ophthalmic suspension 0.1% (Nevanac; Alcon Laboratories, Inc.) for treating cystoid macular edema (CME) resulting from uveitis.

Interventional case series

: Three patients with a history of decreased visual acuity due to uveitic CME despite previous treatment with topical steroids or traditional nonsteroidal antiinflammatory drugs, intravitreal triamcinolone acetonide (Kenalog; Bristol-Myers Squibb), or immunosuppressive agents were given topical nepafenac 0.1%. Patients were monitored for clinical improvement, decreased retinal thickness by optical coherence tomography, and improved Snellen visual acuity.

For all three patients, treatment with topical nepafenac for 4 weeks to 3 months led to improvement in visual acuity and decrease in retinal thickness.

The improved visual acuity and decreased retinal thickness in these patients suggest that nepafenac is an effective treatment of inflammation and CME in the posterior segment of the eye for patients with chronic uveitis.